FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年11月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

授出購股權詳情 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2024年11月14 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向三名承授人授出可認購 合共3,628股美國存託股份的購股權並向一百四十七名承授人授出涉及合共36,689 股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的購股權 於2024年11月14日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予三名 承授人可認購合共3,628股美國存託股份的購股權。 購股權詳情如下： 授出日期： 2024年11月14日 承授人數目： 三名 已授出購股權涉及的相關股份數目： 47,164 購股權總數（美國存託股份）: 3,628 因已授出購股權獲行使而可予認購的 新美國 ...

美国证券交易委员会 华盛顿特区 20549 8-K 表格 _____________________ 根据 1934 年证券交易法 第 13 或 15（d）条规定提交的 临时报告 报告日期（所报告最早事件之日期）：2024 年 11 月 14 日 百济神州有限公司 BEIGENE, LTD. （主要办事处地址）（邮政编码） +1 (345) 949 4123 （注册人电话号码，包括区号） （注册人章程中列明的注册人准确名称） 开曼群岛 001-37686 98-1209416 （注册地所在州或其他司法管辖区） （委员会档案编号） （国税局雇主识别号） c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 Cayman Islands 不适用 （如自上一份报告起有改动，则为公司曾用名或原地址） 若 8-K 表格的呈递旨在同时满足下列任何条例项下的注册人报告义务，请勾选相应方格： ☐ 根据证券法第 425 条发出书面通讯 (17 CFR 230.425) ☐ 根据交易 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has experienced rapid revenue growth, with total revenue reaching $1.002 billion in Q3 2024, representing a year-on-year increase of 28%. The revenue for Q1-Q3 2024 was $750 million, $930 million, and $1.000 billion respectively, with Q3 showing a quarter-on-quarter increase of 7.6%. The European and American markets contributed over 76% of the revenue. The global sales of Zebutinib reached $690 million (+93%), with U.S. sales at $504 million (+87%) and European sales at $97 million (+141%). The sales of Tislelizumab in Q3 2024 were $167 million (+16%) [2][3] Financial Forecast and Valuation - The company is projected to achieve revenues of 255.3 billion yuan, 340.6 billion yuan, and 423.8 billion yuan for the years 2024, 2025, and 2026 respectively. The continuous high growth in sales of core products and the opening of overseas markets indicate a high certainty of growth, leading to the maintained "Buy" rating [4]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 159.00, indicating a potential upside of 38.0% from the current closing price of HKD 115.20 [7]. Core Insights - The company has shown strong sales growth in Q3 2024, with total revenue increasing by 28.2% year-on-year to USD 1.002 billion, driven primarily by a 66.9% increase in product revenue to USD 993 million [1]. - The sales of the drug Zebutinib reached USD 690 million globally, marking a 93.0% year-on-year increase, with a notable performance in the U.S. market [1][2]. - The adjusted non-GAAP operating profit for Q3 2024 was USD 65.63 million, marking the second consecutive quarter of positive operating profit [1]. - The company is expected to continue facing accelerated depreciation costs in Q4 2024, but profitability is anticipated to improve as product volumes increase in the following year [1]. Financial Forecast Changes - Revenue forecasts for 2024-2026 have been increased by 6-7%, with peak sales for Zebutinib revised up by 4% to USD 5.4 billion [2]. - The new revenue projections for 2024, 2025, and 2026 are USD 3.712 billion, USD 4.630 billion, and USD 5.566 billion, respectively, reflecting a 7% increase for 2024 [3]. - The gross profit for 2024 is projected at USD 3.108 billion, with a gross margin of 83.6% [3]. Key Developments - The report highlights several upcoming catalysts, including potential approvals for additional indications of the drug Tarelizumab in key markets and the initiation of Phase III studies for the Bcl-2 inhibitor sonrotoclax in early 2025 [2]. - The company is also advancing multiple candidates for solid tumors into clinical stages, with eight candidates already in clinical trials this year [2]. Financial Data Overview - The company reported a net loss of USD 698 million for 2024, with expectations of narrowing losses in subsequent years [8]. - Cash and cash equivalents are projected to decrease to USD 2.551 billion in 2024, with a gradual recovery expected in 2025 [8].

港股代码：06160 港股简称：百济神州 美股代码：BGNE 重要内容提示： 百济神州有限公司（以下简称"公司"或"本公司"）拟通过在瑞士存 续注册为股份公司并在开曼群岛撤销注册的方式，将本公司注册地由 开曼群岛变更为瑞士（以下简称"拟议存续注册"），并采纳根据瑞士法 律制定的公司章程（以下简称"拟议瑞士章程"）。 A股代码：688235 A股简称：百济神州 公告编号：2024-028 百济神州有限公司 关于拟议变更公司英文名称的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 英文名称变更事项已经公司董事会审议通过，尚需提交公司股东 大会进行审议（其将体现于拟议瑞士章程中，与拟议瑞士章程一并提 交公司股东大会进行审议）。 英文名称变更的前提条件是实施拟议存续注册的相关前提条件得 以实现。 公司股东和潜在投资者应注意，本公告所述事项的实施须满足相 关前提条件，因此，其实施存在不确定性。 公司将根据相关事项的进展情况及时履行信息披露义务，敬请广 大投资者注意投资风险。 特此公告。 百济神州有限公司董事会 公司拟将其英文 ...

Financial Performance - In Q3 2024, the company's product revenue reached 7.079 billion CNY, a year-on-year increase of 65.1% [3] - Global sales of Baiyueze® totaled 4.914 billion CNY, with a year-on-year growth of 91.1% [6] - Sales of Baizean® amounted to 1.169 billion CNY, reflecting an 11.7% increase year-on-year [7] - The company's total revenue for Q3 2024 was 1.002 billion USD, compared to 781 million USD in the same period last year, marking an 87% increase in US and 217% in Europe [5] Market Position - Baiyueze® has solidified its leadership in the hematological oncology field, with significant sales growth in the US (3.584 billion CNY, 85.0% increase) and Europe (693 million CNY, 212.7% increase) [6] - Baizean® has achieved a leading market share in the PD-1 field in China, with 14 approved indications, 11 of which are included in the National Medical Insurance Directory [7] R&D Progress - The company is advancing its pipeline with 4 new molecular entities entering clinical development in Q3 2024, aiming for over 10 new entities by year-end [9] - Key research projects in the CLL field are progressing, with over 1,300 participants enrolled in clinical trials for sonrotoclax [9] - The company has a robust clinical development strategy, with a focus on rapid generation of early clinical concept validation data [11] Strategic Initiatives - The company is expanding its global commercialization capabilities and focusing on developing early and late-stage assets [12] - It is leveraging three core platform technologies: multi-specific antibodies, protein degradation agents, and antibody-drug conjugates to enhance its oncology portfolio [13]

Investment Rating - The report maintains a "Buy" rating for the US and Hong Kong stocks of BeiGene, with target prices adjusted to $255 and HK$153 respectively. The A-share rating is downgraded to "Hold" with a target price of RMB 181 [1][3][7]. Core Insights - The report highlights that BeiGene's total revenue for Q3 2024 reached $1.002 billion, representing a year-over-year increase of 28.2% and a quarter-over-quarter increase of 7.8%. Product revenue was $993 million, up 66.9% year-over-year and 7.8% quarter-over-quarter, slightly below expectations due to lower-than-expected sales of Zanubrutinib in the US [1][3][4]. - The global sales of Zanubrutinib in Q3 2024 amounted to $690 million, a 93.0% increase year-over-year and an 8.3% increase quarter-over-quarter. US sales were $504 million, up 86.5% year-over-year, while European sales surged by 217.2% year-over-year to $97.3 million [1][3][4]. - The report notes a temporary decline in gross margin due to accelerated depreciation from new production lines, with an overall product gross margin of 82.8% in Q3 2024 [1][3][4]. Financial Performance Summary - For Q3 2024, the adjusted non-GAAP operating profit was $65.63 million, an improvement from $48.46 million in Q2 2023. The net loss for the quarter was $121 million, which aligns with expectations but is lower than previous forecasts due to slightly lower revenue gross margins and higher R&D expenses [1][3][4]. - The report projects a slight reduction in revenue forecasts for 2024, with net losses adjusted to $740 million for 2024 and $350 million for 2025, while estimating a near breakeven point by 2026 [3][4]. R&D Pipeline Progress - The report indicates that BeiGene's R&D pipeline is progressing well, with key focus areas including BCL2, BTK CDAC, and CDK4 inhibitors. The BCL2 project has enrolled over 1,300 patients, with several trials expected to complete enrollment by early 2025 [2][3][4]. - The company anticipates that by the end of 2024, a total of 12 solid tumor products will enter clinical trials, with 8 already initiated this year [2].

Investment Rating - Maintain BUY with a target price of US$276.02, down from the previous target price of US$288.93, indicating a potential upside of 42.5% from the current price of US$193.64 [3][21]. Core Insights - BeiGene reported strong product sales of US$993 million in 3Q24, representing an 8% quarter-over-quarter increase and a 67% year-over-year increase. Total product sales for the first nine months of 2024 reached US$2.66 billion, accounting for 69% of the previous full-year estimate [1][2]. - The company achieved non-GAAP profitability with a gross profit margin of 82.8% in 3Q24, despite a decrease from 85.0% in 2Q24 due to accelerated depreciation expenses. The SG&A ratio improved to 46% from 48% in the previous quarter [1][2]. - BeiGene's zanubrutinib (Zanu) sales increased by 8% quarter-over-quarter and 93% year-over-year to US$690 million in 3Q24, capturing approximately 25% of the global BTK inhibitor market [1][2]. Summary by Sections Financial Performance - Revenue for FY24E is projected at US$3.835 billion, with a net profit expected to improve to US$52 million in FY25E, compared to a net loss of US$603 million in FY24E [14][15]. - Gross profit is estimated at US$3.207 billion for FY24E, with a gross margin of 83.63% [16][19]. Product Development - BeiGene is advancing multiple clinical trials, including a Phase 3 study of sonrotoclax combined with zanubrutinib for first-line CLL, with full enrollment expected by 1Q25 [1][2]. - The company is also expanding cohorts for BGB-16673 in R/R CLL and plans to initiate a Phase 3 study for BTK CDAC in R/R CLL in 1H25 [1][2]. Market Position - Zanu continues to outperform competitors, with significant market share gains in the BTK inhibitor market, supported by strong sales growth in both the US and EU [1][2]. - The company is positioned to break even in FY25E, driven by strong sales momentum and improving operating margins [1][2].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Insights - The company reported a total revenue of 19.136 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 48.63%. The adjusted operating loss for the same period was 0.52 billion yuan, significantly improved from a loss of 34.89 billion yuan in the previous year [5][6] - In Q3 2024, the company achieved an adjusted operating profit of 6.44 billion yuan, compared to a loss of 1.47 billion yuan in the same quarter last year, indicating a positive trend in operational efficiency [5][6] - The product revenue for the first three quarters reached 18.986 billion yuan, with Q3 product revenue alone at 7.079 billion yuan, driven by strong sales of Zebrutinib and PD-1 monoclonal antibodies [6] Financial Summary - For the first three quarters of 2024, the company reported a net loss attributable to shareholders of 3.687 billion yuan, an improvement from a loss of 6.716 billion yuan in the same period of 2023 [8] - The projected revenues for 2024 to 2026 are 24.017 billion yuan, 34.325 billion yuan, and 43.351 billion yuan respectively, with corresponding net profits expected to be -4.078 billion yuan, 1.178 billion yuan, and 3.893 billion yuan [8][10] - The gross margin is projected to remain stable around 84.2% to 85.4% from 2024 to 2026 [8] Product Performance - In Q3 2024, Zebrutinib's global sales reached 4.914 billion yuan, with significant growth in the US (3.584 billion yuan, +85.0% YoY) and Europe (0.693 billion yuan, +212.7% YoY) [6] - The sales of PD-1 monoclonal antibodies totaled 1.169 billion yuan in Q3 2024, reflecting a year-on-year increase of 11.7% [6] Pipeline Development - The company is advancing its clinical trials for new generation self-developed pipeline products, with expectations to complete several key trials by 2025 [7] - The company aims to have over 10 new molecular entities enter clinical development by the end of the year [7]